Inpatient prescribing trends and differences in drug acquisition costs of long-acting injectable subcutaneous risperidone versus paliperidone palmitate: A single-center medication use evaluation

Key Points

• Switching to risperidone may lower drug costs in inpatient settings, highlighting financial advantages.
• Drug acquisition costs were critically assessed for both medications, indicating potential savings.
• Evaluation involved direct comparison of long-acting injectables prescribed in a single institution, focusing on formularies.
• Financial considerations are emphasized for administrators when choosing medication post-discharge.

Abstract